Cargando…

Surgery and Prophylaxis with Susoctocog-Alfa in Acquired Hemophilia: Case Series and Literature Review

Background: Acquired hemophilia A (AHA) is a rare bleeding disease due to autoantibodies directed against clotting factor VIII (FVIII). Treatment of AHA consists of inhibitor eradication with immunosuppressive therapy (IST) and prompt control of bleeding obtained with bypassing agents or recombinant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sella, Carola, Bardetta, Marco, Valeri, Federica, Dainese, Cristina, Valpreda, Alessandra, Massaia, Massimo, Grimaldi, Daniele, Porreca, Annamaria, Bruno, Benedetto, Borchiellini, Alessandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380857/ https://www.ncbi.nlm.nih.gov/pubmed/37510704 http://dx.doi.org/10.3390/jcm12144590

Ejemplares similares

Impact of COVID-19 Infection, Vaccination, and Serological Response in Immune Thrombocytopenic Purpura Patients: A Single-Center Global Analysis
por: Dainese, Cristina, et al.
Publicado: (2022)

Analytical Performance of Different Laboratory Methods for Measuring Susoctocog-Alfa
por: Novembrino, Cristina, et al.
Publicado: (2022)

ADAMTS13 Autoantibodies and Burden of Care in Immune Thrombotic Thrombocytopenic purpura: New Evidence and Future Implications
por: Dainese, Cristina, et al.
Publicado: (2022)

Management of patients with bleeding disorders and educational needs regarding hemophilia a in 23 Italian emergency departments – Results from a survey conducted in Piedmont
por: Pollio, Berardino, et al.
Publicado: (2022)

Extended half‐life rFIX in major surgery—How to improve clinical practice: An intraindividual comparison
por: Valeri, Federica, et al.
Publicado: (2020)

Anti-ADAMTS13 Autoantibodies: From Pathophysiology to Prognostic Impact—A Review for Clinicians
por: Dainese, Cristina, et al.
Publicado: (2023)

Treatment of high-risk bleeding with susoctocog alfa in a patient with acquired haemophilia A and a nosocomial severe acute respiratory syndrome coronavirus 2 infection
por: Fernández-Oliveira, Carla, et al.
Publicado: (2023)

Damoctocog Alfa Pegol for Hemophilia A Prophylaxis: An Italian Multicenter Survey
por: Zanon, Ezio
Publicado: (2023)

Cost–consequence analysis of long-term prophylaxis in the treatment of von Willebrand disease in the Italian context
por: Schinco, Piercarla, et al.
Publicado: (2014)

Moroctocog Alfa (AF-CC) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Patients with Hemophilia A in India
por: Choraria, Nirmalkumar, et al.
Publicado: (2022)

Nonacog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Patients with Moderately Severe or Severe Hemophilia B in India
por: Choraria, Nirmalkumar, et al.
Publicado: (2022)

Acquired Hemophilia
por: Özsoylu, Şinasi
Publicado: (2014)

Assessment of Relative Bioavailability of Moroctocog Alfa and Moroctocog Alfa (AF‐CC) in Subjects With Severe Hemophilia A
por: Korth‐Bradley, Joan, et al.
Publicado: (2018)

Profile of efraloctocog alfa and its potential in the treatment of hemophilia A
por: George, Lindsey A, et al.
Publicado: (2015)

The Effect of Fluctuating Temperature on the Stability of Turoctocog Alfa for Hemophilia A
por: Napolitano, Mariasanta, et al.
Publicado: (2019)

Optimization of prophylaxis for hemophilia A
por: Herbert, Robert D., et al.
Publicado: (2018)

Efficacy of Nuwiq(®) (Simoctocog Alfa) in Patients with Hemophilia A Who Changed and Adhered to a Pharmacokinetic-Guided Prophylaxis Regimen in the NuPreviq Study
por: Pasi, K John
Publicado: (2021)

Indirect Treatment Comparison of Damoctocog Alfa Pegol versus Turoctocog Alfa Pegol as Prophylactic Treatment in Patients with Hemophilia A
por: Vashi, Parth, et al.
Publicado: (2021)

Correction: Optimization of prophylaxis for hemophilia A
por: Herbert, Robert D., et al.
Publicado: (2018)

Pharmacokinetics of recombinant factor VIII in adults with severe hemophilia A: fixed-sequence single-dose study of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfa
por: Lissitchkov, Toshko, et al.
Publicado: (2023)

Turoctocog alfa: an evidence-based review of its potential in the treatment of hemophilia A
por: Takedani, Hideyuki, et al.
Publicado: (2015)

Efficacy, Safety, and Pharmacokinetics of Beroctocog Alfa in Patients Previously Treated for Hemophilia A
por: Hyun, Shin Young, et al.
Publicado: (2015)

A Case of Acquired Hemophilia A and Congenital Hemophilia B
por: Fortier, Julia C, et al.
Publicado: (2022)

Principles of care for acquired hemophilia
por: Dolan, Gerry, et al.
Publicado: (2021)

Hemophilia prophylaxis adherence and bleeding using a tailored, frequency‐escalated approach: The Canadian Hemophilia Primary Prophylaxis Study
por: Dover, Saunya, et al.
Publicado: (2020)

Apixaban and eftrenonacog alfa treatment in a patient with moderate hemophilia B and cardiovascular disease
por: Santoro, Rita C., et al.
Publicado: (2021)

Acquired Hemophilia A with Gastrointestinal Bleeding
por: Park, Narae, et al.
Publicado: (2020)

Acquired Hemophilia A and urothelial carcinoma
por: Taza, Fadi, et al.
Publicado: (2021)

SARS-CoV-2 infection, vaccination and acquired hemophilia: Reply
por: Franchini, Massimo, et al.
Publicado: (2023)

Hematuria in aging men with hemophilia: Association with factor prophylaxis
por: Qvigstad, Christian, et al.
Publicado: (2020)

Turoctocog alfa is safe for the treatment of Indian patients with hemophilia A: Guardian 10 trial results
por: John, M. Joseph, et al.
Publicado: (2020)

Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study
por: Lissitchkov, Toshko, et al.
Publicado: (2022)

Neurosurgery in a patient with severe hemophilia B: an experience using eftrenonacog alfa as perioperative management
por: Benitez Hidalgo, Olga, et al.
Publicado: (2022)

Real-World Use of Albutrepenonacog Alfa, A Recombinant Coagulation Factor IX Albumin Fusion Protein, for Personalized Prophylaxis in Japanese Individuals With Hemophilia B: A Case Series
por: Nagao, Azusa, et al.
Publicado: (2023)

An acquired factor V inhibitor induced uncontrolled bleeding in a postsurgery patient
por: Bruna, Riccardo, et al.
Publicado: (2020)

Current Choices and Management of Treatment in Persons with Severe Hemophilia A without Inhibitors: A Mini-Delphi Consensus
por: Coppola, Antonio, et al.
Publicado: (2022)

Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors
por: Shapiro, Amy D., et al.
Publicado: (2022)

Acquired hemophilia A: emerging treatment options
por: Janbain, Maissaa, et al.
Publicado: (2015)

Acquired Hemophilia A Successfully Treated with Rituximab
por: D’Arena, Giovanni, et al.
Publicado: (2015)

Management of Acquired Hemophilia A in Elderly Patients
por: Yamaguchi, Tomoya, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0np742j2r845i6vd7umur101qo